Increasing CRPM levels following antifibrotic therapy in IPF is associated with adverse outcomes with nintedanib, but not pirfenidone - Milan 2023

Biomarkers in interstitial lung disease

Chair(s): Manuela Funke-Chambour, Stephane Jouneau

Session type: Poster session

Increasing CRPM levels following antifibrotic therapy in IPF is associated with adverse outcomes with nintedanib, but not pirfenidone

Jannik Ruwisch

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Exploring the Potential of Serum Periostin as a Predictive biomarker for Early-Onset Idiopathic Pulmonary Fibrosis: A Follow-Up Study

Mingtao Liu

Poster

Abstract

A combined measure of blood leukocytes, FVC and quantitative CT is highly predictive of mortality in idiopathic pulmonary fibrosis (IPF)

Andrew Achaiah

Poster

Abstract

Longitudinal changes in CT quantified pulmonary artery volume and interstitial abnormalities correlate with pulmonary function decline in IPF patients

Anne-noelle Frix

Poster

Abstract

Predicting factors of acute exacerbation of idiopathic pulmonary fibrosis

Morgane Browarski

Poster

Abstract

Two CT image-based Biomarkers for Predicting Progression in fibrosing interstitial lung diseases

Ju Hyun Oh

Poster

Abstract

Differential blood count as a prognostic tool in interstitial lung diseases

Nimrod Orr Urtreger

Poster

Abstract

Serum Krebs von den Lungen-6 (KL-6) level as a prognostic biomarker in patients with interstitial lung abnormalities (ILA)

Hye Kyeong Park

Poster

Abstract

Blood gene expression is associated with decline in lung function in interstitial lung disease

Daniel He

Poster

Abstract

CT-derived biomarkers as predictors of overall survival in patients with idiopathic pulmonary fibrosis (IPF)

Francesco Bonella

Poster

Abstract

Lactate dehydrogenase predicts disease progression in patients with IPF

Nils Hoyer

Poster

Abstract

Prognostic value of circulating biomarkers in patients with progressive pulmonary fibrosis

Francesco Bonella

Poster

Abstract

Lipid metabolism in interstitial lung diseases: serum amyloid A a new potential biomarker in idiopathic pulmonary fibrosis

Lucia Vietri

Poster

Abstract

Osteopontin as a biomarker in interstitial lung diseases

David Iturbe Fernandez

Poster

Abstract

Histological and molecular characterization of lung cancer (LC) in patients with and without interstitial lung disease (ILD)

Gioele Castelli

Poster

Abstract

Machine learning-based identification of RNA and protein biomarkers predictive of disease progression or death in the IPF-PRO Registry

Kolja Becker

Poster

Abstract

Circulating prostasin associates with presence and severity of idiopathic pulmonary fibrosis (IPF)

Jamie Todd

Poster

Abstract

Clinical utility of heparin-binding protein as an acute-phase inflammatory marker in interstitial lung disease

Xue Mingshan

Poster

Abstract

Circulating biomarkers in children and adolescents with fibrosing interstitial lung disease (ILD)

Robin Deterding

Poster

Abstract

Associations between neutrophil and lymphocyte counts and ILD progression in subjects with progressive fibrosing ILDs

Michael Kreuter

Poster

Abstract

Increasing CRPM levels following antifibrotic therapy in IPF is associated with adverse outcomes with nintedanib, but not pirfenidone

Jannik Ruwisch

Poster

Abstract

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}